<PAGE> 1
July 19, 1996
VIA EDGAR
- ---------
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Target Therapeutics, Inc.
Registration No. 333-8075
Registration Statement on Form S-3
Ladies and Gentlemen:
We are writing to you on behalf of our client, Target
Therapeutics, Inc. (the "Registrant"), in connection with the proposed
registration of 143,775 shares of the Registrant's Common Stock under the
Securities Act of 1933, as amended (the "Act") pursuant to the Registration
Statement set forth above. Due to an administrative oversight, we inadvertently
omitted from the Registration Statement the following language pursuant to Rule
473 of the Act:
"The Registrant hereby amends this Registration Statement on such date
or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that
this Registration Statement shall thereafter become effective in accordance
with Section 8(A) of the Securities Act of 1933, as amended, or until the
Registration Statement shall become effective on such date as the
Commission, acting pursuant to said Section 8(A), may determine."
We hereby would like this language incorporated by reference into the
Registrant's Registration Statement on Form S-3. We will include this language
in the first amendment to the Registration Statement.
If you have any questions or comments, please feel free to call me at
(415) 233-8408.
Sincerely,
VENTURE LAW GROUP
A Professional Corporation
/s/ Amy L. Custalow
Amy L. Custalow
cc: Kathleen Haller (SEC)
Robert E. McNamara (Target)
David A. Garcia (VLG)
